Prevention & lipids

Statin–Ezetimibe Therapy and Incident Myocardial Infarction Across Modified Cardiovascular–Kidney–Metabolic Risk Groups: A Nationwide Target Trial Emulation

Eur Heart J Cardiovasc PharmacotherPublished Nationwide target trial emulation

Main finding · Myocardial infarction risk, modified early-risk participantsResult — go to the resultHazard ratio 0.87 95% CI 0.81–0.95

Authors' conclusion

Among adults with dyslipidemia who received prescriptions covering a total of 180 days, statin-ezetimibe combination therapy was associated with a lower subsequent risk of myocardial infarction than statin monotherapy across modified CKM risk groups. The association was most evident in moderate-intensity comparisons.

Study context

Population
Adults aged 30–74 years with dyslipidemia who received prescriptions covering a total of 180 days with statin monotherapy or a fixed-dose statin-ezetimibe combination, Korean National Health Insurance Service database239,954 (modified early risk) · 69,417 (modified late risk)
Participants
309,371 treated participants
Comparison
Statin-ezetimibe therapy vs statin monotherapy, treatment assigned at the 180-day landmark
Outcome
Myocardial infarction risk, modified early-risk participants
Methodological detailsseparate two-arm landmark target trials within modified early and late cardiovascular-kidney-metabolic risk groups, stabilized inverse probability of treatment weighting, cause-specific Cox regression, death treated as a competing event for cumulative incidence estimation
  • Separate two-arm landmark target trials within modified early and late cardiovascular-kidney-metabolic risk groups
  • Stabilized inverse probability of treatment weighting
  • Cause-specific Cox regression
  • Death treated as a competing event for cumulative incidence estimation

Main finding

As reported in the abstract

Myocardial infarction risk, modified early-risk participants

Hazard ratio

0.87

95% CI 0.81–0.95

Statin-ezetimibevs Statin monotherapy
HR 0.87 (95% CI 0.81–0.95)

Further findings

OutcomeHR (95% CI)
Myocardial infarction risk, modified late-risk participantsAfter weighting0.88 (0.79–0.98)
Myocardial infarction, same-intensity comparison, moderate-intensity therapy, early CKM groupAssociation most evident with moderate-intensity therapy0.87 (0.79–0.95)

Myocardial infarction, 10-year weighted cumulative incidence, early-risk and late-risk groups

Weighted cumulative incidence reported for each risk group; the abstract does not state which value belongs to which treatment group

Original publication

Statin–Ezetimibe Therapy and Incident Myocardial Infarction Across Modified Cardiovascular–Kidney–Metabolic Risk Groups: A Nationwide Target Trial Emulation. Eur Heart J Cardiovasc Pharmacother. Published 13 November 2026. doi:10.1093/ehjcvp/pvag099

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.